Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

Journal article

PURPOSE: Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer. PATIENTS AND METHODS: Oral nelfinavir (2 x 1,250 mg) was started 3 days before and continued throughout chemoradiotherapy to 50.4 Gy (boost, 59.4 Gy) in 12 patients. Two gemcitabine dose levels (DL) were tested (200 mg/m(2) and 300 mg/m(2) on days 1, 8, 22, and 29). C...

Expand abstract

Authors: Brunner, T; Geiger, M; Grabenbauer, G; Lang-Welzenbach, M; Mantoni, T

• Publication status: Published
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• Volume: 26
• Issue: 16
• Pages: 2699-2706
• Publication date: 2008-06-01
• DOI: 10.1200/jco.2007.15.2355
• EISSN: 1527-7755
• ISSN: 0732-183X
• Language: English
• Keywords: Humans; Middle Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Nelfinavir; Cisplatin; Male; Pancreatic Neoplasms; HIV Protease Inhibitors; Aged; Combined Modality Therapy; Deoxycytidine; Treatment Outcome